inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2500-0268-2021-24-4-67-72inovmed-473Research ArticleОБЗОРЫREVIEWSБиомаркеры сердечной недостаточности: современное состояние вопросаBiomarkers of heart failure: current state of problemhttps://orcid.org/0000-0003-0013-1425ИшевскаяО. П.IshevskaiaO. P.

Ишевская Ольга Петровна, аспирант кафедры терапии№ 1 ФПК и ППС

350063, Краснодар, ул. М. Седина, 4,

Olga P. Ishevskaia, Postgraduate Student of the Therapy Department

4, M. Sedina str., Krasnodar, 350063

ishevska@yandex.ruhttps://orcid.org/0000-0002-5866-506XНамитоковА. М.NamitokovA. M.

Намитоков Алим Муратович, к. м. н., ассистент кафедрытерапии № 1 ФПК и ППС; заведующий кардиологическим отделением № 2 для больных с инфарктом миокарда

Краснодар

Alim M. Namitokov, Cand. of Sci. (Med.), Assistant Professor,Therapy Department no. 1; Head of the Cardiology Department no. 2 for patients with myocardial infarction

Krasnodar

https://orcid.org/0000-0001-8600-0199КосмачеваЕ. Д.KosmachevaE. D.

Космачева Елена Дмитриевна, д. м. н., зав. кафедройтерапии № 1 ФПК и ППС; заместитель главного врача по лечебной работе 

Краснодар

Elena D. Kosmacheva, Dr. of Sci. (Med.), Head of the TherapyDepartment no. 1; Deputy Chief Physician for Medical Work

Krasnodar

Кубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian FederationКубанский государственный медицинский университет; Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. ОчаповскогоРоссияKuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1Russian Federation202130122021046772Copyright © Ишевская О.П., Намитоков А.М., Космачева Е.Д., 20212021Ишевская О.П., Намитоков А.М., Космачева Е.Д.Ishevskaia O.P., Namitokov A.M., Kosmacheva E.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/473

Ежегодно во всем мире наблюдается прирост числа пациентов с сердечной недостаточностью (СН). Ранняя диагностика состояния и прогнозирование неблагоприятного течения позволяют усовершенствовать тактику ведения пациентов и замедлить прогрессирование заболевания. В настоящий момент наиболее универсальным биомаркером СН считается предшественник мозгового натрийуретического пептида (NT-proBNP), однако и он обладает рядом недостатков. Поиск идеального биомаркера направлен в область молекулярной биологии и генетики. Микрорибонуклеиновые кислоты (микроРНК) выполняют в организме регулирующие функции, обладают кардиоспецифичностью и плазменной устойчивостью.

В ряде исследований микроРНК показали сопоставимую с NT-proBNP диагностическую и прогностическую ценность. Кроме того, потенциальные возможности метода не ограничиваются только диагностикой. МикроРНК могут также использоваться в качестве терапевтических мишеней лечения СН.

There is constant increase in patients with heart failure every year worldwide. Early diagnosis and prediction of deterioration could upgrade management of patients and slow down the progression of heart failure.

The brain natriuretic peptide precursor (NT-proBNP) is considered to be the universal biomarker, although it has several limitations. The search of ideal biomarker is directed into molecular biology and genetics. Microribonucleic acids (microRNAs) regulate different processes in human body, present myocardial specificity, and plasma stability. It has been proven in different trials that diagnostic and prognostic level of microRNAs is equal to NT-proBNP. Potential opportunities of the method are not only diagnosis but therapeutic targets for heart failure

сердечная недостаточностьбиомаркернатрийуретический пропептидмикроРНКheart failurebiomarkerNT-proBNPmicroRNAReferencesPonikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200. https://doi. org/10.1093/eurheartj/ehw128Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200. https://doi. org/10.1093/eurheartj/ehw128Ponikowski P, Anker SD, AlHabib KF, et al. Heart faliure: reventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25. https://doi.org/10.1002/ehf2.12005Ponikowski P, Anker SD, AlHabib KF, et al. Heart faliure: reventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25. https://doi.org/10.1002/ehf2.12005Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276–289. https://doi.org/10.1038/nrcardio.2014.26Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276–289. https://doi.org/10.1038/nrcardio.2014.26Nagavi M, Wang H, Lozano R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013:Asystematic analysisfortheGlobal Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2Nagavi M, Wang H, Lozano R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013:Asystematic analysisfortheGlobal Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation. 2002;106(24):3068–3072. http://doi. org/10.1161/01.CIR.0000039105.49749.6FLloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation. 2002;106(24):3068–3072. http://doi. org/10.1161/01.CIR.0000039105.49749.6FAtkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. https://doi.org/10.1067/mcp.2001.113989Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. https://doi.org/10.1067/mcp.2001.113989VasanRS.Biomarkersofcardiovasculardisease:Molecular basis and practical considerations.Circulation. 2006;113(19):2335– 2362. https://doi.org/10.1161/CIRCULATIONAHA.104.482570VasanRS.Biomarkersofcardiovasculardisease:Molecular basis and practical considerations.Circulation. 2006;113(19):2335– 2362. https://doi.org/10.1161/CIRCULATIONAHA.104.482570Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American heart association. Circulation. 2009;119(17):2408–2416. https://doi.org/10.1161/ CIRCULATIONAHA.109.192278Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American heart association. Circulation. 2009;119(17):2408–2416. https://doi.org/10.1161/ CIRCULATIONAHA.109.192278MorrowDA,DeLemosJA.Benchmarksforthe assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949– 952. https://doi.org/10.1161/CIRCULATIONAHA.106.683110MorrowDA,DeLemosJA.Benchmarksforthe assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949– 952. https://doi.org/10.1161/CIRCULATIONAHA.106.683110Tang WHW, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116(5):99–109. https://doi.org/10.1161/ CIRCULATIONAHA.107.185267Tang WHW, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116(5):99–109. https://doi.org/10.1161/ CIRCULATIONAHA.107.185267Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry. 2017;79:93–152. https:// doi.org/10.1016/bs.acc.2016.09.002Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry. 2017;79:93–152. https:// doi.org/10.1016/bs.acc.2016.09.002Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/ AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):147–239. https://doi.org/10.1016/j.jacc.2013.05.019Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/ AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):147–239. https://doi.org/10.1016/j.jacc.2013.05.019Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1–2. https://doi.org/10.1016/j.cardfail.2010.04.004Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1–2. https://doi.org/10.1016/j.cardfail.2010.04.004Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/ HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161. https://doi.org/10.1161/ CIR.0000000000000509Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/ HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161. https://doi.org/10.1161/ CIR.0000000000000509Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022Bachmann KN, Gupta DK, Xu M, et al. Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. JACC Hear Fail. 2021;9(3):192–200. https://doi.org/10.1016/j. jchf.2020.10.008Bachmann KN, Gupta DK, Xu M, et al. Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. JACC Hear Fail. 2021;9(3):192–200. https://doi.org/10.1016/j. jchf.2020.10.008Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2):345–353. https://doi.org/10.1016/j.jacc.2005.09.025Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2):345–353. https://doi.org/10.1016/j.jacc.2005.09.025Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: The framingham heart study. Circulation. 2012;126(13):1596–1604. https://doi.org/10.1161/CIRCULATIONAHA.112.129437Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: The framingham heart study. Circulation. 2012;126(13):1596–1604. https://doi.org/10.1161/CIRCULATIONAHA.112.129437Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019;73(11):1273–1284. https://doi.org/10.1016/j. jacc.2018.12.063Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019;73(11):1273–1284. https://doi.org/10.1016/j. jacc.2018.12.063Richards M, Di Somma S, Mueller C, et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH study (Biomarkers in ACute Heart Failure). JACC Hear Fail. 2013;1(3):192–199. https://doi.org/10.1016/j.jchf.2013.02.004Richards M, Di Somma S, Mueller C, et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH study (Biomarkers in ACute Heart Failure). JACC Hear Fail. 2013;1(3):192–199. https://doi.org/10.1016/j.jchf.2013.02.004De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3(3):215–224. https://doi.org/10.1001/jamacardio.2017.4987De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3(3):215–224. https://doi.org/10.1001/jamacardio.2017.4987Apple FS, Cullen L, Felker GM, Ginsburg G, Morrow D. Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics. Clin Chem. 2017;63(1):1–4. https://doi.org/10.1373/ clinchem.2016.263350Apple FS, Cullen L, Felker GM, Ginsburg G, Morrow D. Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics. Clin Chem. 2017;63(1):1–4. https://doi.org/10.1373/ clinchem.2016.263350Edwards AVG, White MY, Cordwell SJ. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics. 2008;7(10):1824–1837. https://doi.org/10.1074/ mcp.R800007-MCP200Edwards AVG, White MY, Cordwell SJ. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics. 2008;7(10):1824–1837. https://doi.org/10.1074/ mcp.R800007-MCP200Cappola TP, Matkovich SJ, Wang W, et al. Loss-offunction DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci USA. 2011;108(6):2456–2461. https://doi.org/10.1073/pnas.1017494108Cappola TP, Matkovich SJ, Wang W, et al. Loss-offunction DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci USA. 2011;108(6):2456–2461. https://doi.org/10.1073/pnas.1017494108Villard E, Perret C, Gary F, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32(9):1065– 1076. https://doi.org/10.1093/eurheartj/ehr105Villard E, Perret C, Gary F, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32(9):1065– 1076. https://doi.org/10.1093/eurheartj/ehr105Meder B, Haas J, Sedaghat-Hamedani F, et al. Epigenome-Wide Association Study Identifies Cardiac Gene Patterning and a Novel Class of Biomarkers for Heart Failure. Circulation. 2017;136(16):1528-1544. https://doi.org/10.1161/ CIRCULATIONAHA.117.027355Meder B, Haas J, Sedaghat-Hamedani F, et al. Epigenome-Wide Association Study Identifies Cardiac Gene Patterning and a Novel Class of Biomarkers for Heart Failure. Circulation. 2017;136(16):1528-1544. https://doi.org/10.1161/ CIRCULATIONAHA.117.027355Toma M, Mak GJ, Chen V, et al. Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Hear Fail. 2017;4(3):301–311. https://doi. org/10.1002/ehf2.12136Toma M, Mak GJ, Chen V, et al. Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Hear Fail. 2017;4(3):301–311. https://doi. org/10.1002/ehf2.12136Stenemo M, Nowak C, Byberg L, et al. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail. 2018;20(1):55–62. https://doi.org/10.1002/ejhf.980Stenemo M, Nowak C, Byberg L, et al. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail. 2018;20(1):55–62. https://doi.org/10.1002/ejhf.980Brioschi M, Gianazza E, Agostoni P, Zoanni B, Mallia A, Banfi C. Multiplexed MRM-based proteomics identified multiple biomarkers of disease severity in human heart failure. Int J Mol Sci. 2021;22(2):1–15. https://doi.org/10.3390/ijms22020838Brioschi M, Gianazza E, Agostoni P, Zoanni B, Mallia A, Banfi C. Multiplexed MRM-based proteomics identified multiple biomarkers of disease severity in human heart failure. Int J Mol Sci. 2021;22(2):1–15. https://doi.org/10.3390/ijms22020838Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860– 921. https://doi.org/10.1038/35057062Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860– 921. https://doi.org/10.1038/35057062Gomes CPDC, Schroen B, Kuster GM, et al. Regulatory RNAs in Heart Failure. Circulation. 2020;141:313–328. https:// doi.org/10.1161/CIRCULATIONAHA.119.042474Gomes CPDC, Schroen B, Kuster GM, et al. Regulatory RNAs in Heart Failure. Circulation. 2020;141:313–328. https:// doi.org/10.1161/CIRCULATIONAHA.119.042474PritchardCC,Cheng HH,Tewari M. MicroRNAprofiling: approaches and considerations. Nat Rev Genet. 2012;13(5):358– 369. https://doi.org/10.1038/nrg3198PritchardCC,Cheng HH,Tewari M. MicroRNAprofiling: approaches and considerations. Nat Rev Genet. 2012;13(5):358– 369. https://doi.org/10.1038/nrg3198Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–D162. https://doi.org/10.1093/nar/gky1141Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–D162. https://doi.org/10.1093/nar/gky1141Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613–618. https://doi.org/10.1038/nm1582Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613–618. https://doi.org/10.1038/nm1582Van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103(48):18255–18260. https://doi.org/10.1073/ pnas.0608791103Van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103(48):18255–18260. https://doi.org/10.1073/ pnas.0608791103Nagpal V, Rai R, Place AT, et al. MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis. Circulation. 2016;133(3):291–301. https://doi.org/10.1161/ CIRCULATIONAHA.115.018174Nagpal V, Rai R, Place AT, et al. MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis. Circulation. 2016;133(3):291–301. https://doi.org/10.1161/ CIRCULATIONAHA.115.018174Kim IM, Wang Y, Park KM, et al. β-arrestin1-biased β1-adrenergic receptor signaling regulates MicroRNA processing. Circ Res. 2014;114(5):833–844. https://doi.org/10.1161/ CIRCRESAHA.114.302766Kim IM, Wang Y, Park KM, et al. β-arrestin1-biased β1-adrenergic receptor signaling regulates MicroRNA processing. Circ Res. 2014;114(5):833–844. https://doi.org/10.1161/ CIRCRESAHA.114.302766Kumarswamy R, Lyon AR, Volkmann I, et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J. 2012;33(9):1067– 1075. https://doi.org/10.1093/eurheartj/ehs043Kumarswamy R, Lyon AR, Volkmann I, et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J. 2012;33(9):1067– 1075. https://doi.org/10.1093/eurheartj/ehs043Perrino C, Barabási AL, Condorelli G, et al. Epigenomic and transcriptomic approaches in the post-genomic era: Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2017;113(7):725–736. https://doi.org/10.1093/cvr/cvx070Perrino C, Barabási AL, Condorelli G, et al. Epigenomic and transcriptomic approaches in the post-genomic era: Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2017;113(7):725–736. https://doi.org/10.1093/cvr/cvx070Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–154. https://doi.org/10.1093/eurjhf/hfr155Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–154. https://doi.org/10.1093/eurjhf/hfr155Seronde MF, Vausort M, Gayat E, et al. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One. 2015;10(11):е0142237. https://doi.org/10.1371/journal. pone.0142237Seronde MF, Vausort M, Gayat E, et al. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One. 2015;10(11):е0142237. https://doi.org/10.1371/journal. pone.0142237Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186–2194. https://doi.org/10.1016/j. ijcard.2013.01.228Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186–2194. https://doi.org/10.1016/j. ijcard.2013.01.228Wong LL, Zou R, Zhou L, et al. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. J Am Coll Cardiol. 2019;73(11):1300–1313. https://doi. org/10.1016/j.jacc.2018.11.060Wong LL, Zou R, Zhou L, et al. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. J Am Coll Cardiol. 2019;73(11):1300–1313. https://doi. org/10.1016/j.jacc.2018.11.060Stojkovic S, Koller L, Sulzgruber P, et al. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. Int J Cardiol. 2020;303:80–85. https://doi. org/10.1016/j.ijcard.2019.11.090Stojkovic S, Koller L, Sulzgruber P, et al. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. Int J Cardiol. 2020;303:80–85. https://doi. org/10.1016/j.ijcard.2019.11.090Mavrakis KJ, Wolfe AL, Oricchio E, et al. Genomewide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010;12(4):372–379. https://doi.org/10.1038/ncb2037Mavrakis KJ, Wolfe AL, Oricchio E, et al. Genomewide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010;12(4):372–379. https://doi.org/10.1038/ncb2037Gao Y-H, Qian J-Y, Chen Z-W, et al. Suppression of Bim by microRNA-19a may protect cardiomyocytes against hypoxia-induced cell death via autophagy activation. Toxicol Lett. 2016;257:72–83. https://doi.org/10.1016/j.toxlet.2016.05.019Gao Y-H, Qian J-Y, Chen Z-W, et al. Suppression of Bim by microRNA-19a may protect cardiomyocytes against hypoxia-induced cell death via autophagy activation. Toxicol Lett. 2016;257:72–83. https://doi.org/10.1016/j.toxlet.2016.05.019Gao F, Kataoka M, Liu N, et al. Therapeutic role of miR19a/19b in cardiac regeneration and protection from myocardial infarction. Nat Commun. 2019;10(1). https://doi.org/10.1038/ s41467-019-09530-1Gao F, Kataoka M, Liu N, et al. Therapeutic role of miR19a/19b in cardiac regeneration and protection from myocardial infarction. Nat Commun. 2019;10(1). https://doi.org/10.1038/ s41467-019-09530-1

The authors declare that there are no conflicts of interest present.